Charles River Laboratories International, Inc. (NYSE:CRL) Stock Holdings Decreased by Dai ichi Life Insurance Company Ltd

Dai ichi Life Insurance Company Ltd decreased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 29.2% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 2,430 shares of the medical research company’s stock after selling 1,000 shares during the quarter. Dai ichi Life Insurance Company Ltd’s holdings in Charles River Laboratories International were worth $479,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Tidal Investments LLC increased its stake in Charles River Laboratories International by 99.8% in the 1st quarter. Tidal Investments LLC now owns 5,297 shares of the medical research company’s stock valued at $1,435,000 after buying an additional 2,646 shares during the period. Comerica Bank grew its stake in Charles River Laboratories International by 5.6% in the first quarter. Comerica Bank now owns 17,514 shares of the medical research company’s stock valued at $4,745,000 after purchasing an additional 927 shares in the last quarter. Atria Investments Inc increased its position in Charles River Laboratories International by 19.6% in the 1st quarter. Atria Investments Inc now owns 17,502 shares of the medical research company’s stock worth $4,742,000 after purchasing an additional 2,873 shares during the last quarter. Cetera Investment Advisers raised its stake in shares of Charles River Laboratories International by 223.4% during the 1st quarter. Cetera Investment Advisers now owns 9,740 shares of the medical research company’s stock worth $2,639,000 after purchasing an additional 6,728 shares in the last quarter. Finally, Cetera Advisors LLC lifted its holdings in shares of Charles River Laboratories International by 197.1% during the 1st quarter. Cetera Advisors LLC now owns 3,357 shares of the medical research company’s stock valued at $910,000 after buying an additional 2,227 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the sale, the director now owns 12,386 shares in the company, valued at $2,676,862.32. The trade was a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Performance

Shares of NYSE CRL opened at $199.59 on Friday. Charles River Laboratories International, Inc. has a 12 month low of $176.48 and a 12 month high of $275.00. The company has a market cap of $10.21 billion, a P/E ratio of 24.98, a P/E/G ratio of 5.19 and a beta of 1.38. The business’s 50 day moving average is $194.64 and its two-hundred day moving average is $205.19. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.43 by $0.16. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. Charles River Laboratories International’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter last year, the company posted $2.72 earnings per share. On average, equities analysts expect that Charles River Laboratories International, Inc. will post 10.19 EPS for the current year.

Charles River Laboratories International declared that its Board of Directors has approved a share repurchase program on Wednesday, August 7th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the medical research company to buy up to 9.6% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Wall Street Analysts Forecast Growth

CRL has been the topic of a number of research reports. StockNews.com downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. UBS Group raised their price target on shares of Charles River Laboratories International from $240.00 to $250.00 and gave the company a “buy” rating in a report on Thursday, November 7th. The Goldman Sachs Group decreased their price objective on shares of Charles River Laboratories International from $290.00 to $250.00 and set a “buy” rating for the company in a report on Thursday, August 8th. Evercore ISI raised their target price on Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a report on Thursday, November 7th. Finally, Redburn Atlantic assumed coverage on Charles River Laboratories International in a research note on Monday, October 14th. They set a “sell” rating and a $151.00 price target for the company. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $214.38.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).